Completed PHASE2 INTERVENTIONAL 7-arm NCT04227990

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

Sponsor: BeyondSpring Pharmaceuticals Inc.

Conditions Chemotherapy-induced Neutropenia

Interventions Docetaxel, doxorubicin, and cyclophosphamide (TAC) Pegfilgrastim Plinabulin

Updated 6 times since 2020 Last updated: Jan 13, 2020 Started: Nov 27, 2017 Primary completion: Oct 15, 2018 Completion: Jan 3, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chemotherapy-induced Neutropenia and is currently completed. BeyondSpring Pharmaceuticals Inc. leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Jan 2026 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Feb 2020 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeyondSpring Pharmaceuticals Inc.

Data source: BeyondSpring Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Changchun, China , Dnipro, Ukraine , Guangzhou, China , Harbin, China , Ivano-Frankivsk, Ukraine , Kharkiv, Ukraine , Kropyvnytskyi, Ukraine , Krutyi Bereh, Ukraine , Odesa, Ukraine , Shenyang, China and 1 more location